Angiotech announces further European expansion of the Quill(TM) SRS PDO product line
20 September 2007 - 11:22PM
PR Newswire (US)
VANCOUVER, Sept. 20 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced that it has received CE Mark approval to begin marketing
additional diameters of its Quill(TM) Self-Retaining System (SRS)
Polydioxanone (PDO) product line in Europe. The Quill(TM) SRS PDO
is a longer-lasting absorbable suture, which is typically used for
deeper tissue closures. With CE Mark approval to market the
additional 3-0 and 4-0 sizes of Quill(TM) SRS PDO, Angiotech now
offers diameters ranging from sizes 2 to 4-0 in Europe. "The
availability of these additional PDO sizes in Europe will allow our
sales force to offer an even broader range of Quill(TM) SRS
products, ensuring we have multiple solutions for a variety of
wound closure and tissue approximation procedures," said Dr. Santi
Corsaro, Vice President, Sales & Marketing (OUS) for Angiotech.
Angiotech plans to exhibit the Quill(TM) SRS product line at the
upcoming Annual Meeting of the American Society of Plastic Surgeons
(ASPS) to be held on October 26-31, 2007 in Baltimore, MD. About
the Quill(TM) Self-Retaining System (SRS) The innovative Quill(TM)
SRS represents the next generation of wound closure technology. A
patented helical barbed design enables surgeons to suture without
the use of knots. The absence of knots provides a wide range of
clinical and economic benefits, including: Potential to improve
patient outcomes: - Minimizes complications associated with knots -
Potential to improve wound healing - May enhance cosmesis Potential
to save time in the operating room: - Achieves potentially
significant time savings, especially in suture intensive procedures
Enhanced procedural techniques: - Allows closure of difficult
wounds - Enables suturing in tight places - Allows the surgeon to
control tension Note on Forward Looking Statements Statements
contained in this press release that are not based on historical
fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements in this release include but
are not limited to statements regarding: financial benefits to
Angiotech that could potentially be realized from Angiotech's wound
closure business, the ability of Angiotech to commercialize the
Quill(TM) SRS product and to develop and commercialize any
successive product lines, that a substantial market exists for the
product, that the product will perform as expected, that the
product represents an improvement over current wound closure
methods and that these improvements could be beneficial to
physicians and to patients. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following; general economic and business
conditions, both nationally and in the regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and
products; the requirement for substantial funding to conduct
research and development and to expand commercialization
activities; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that
may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from
our actual results. These operating risks include; poor performance
of the product in the clinical setting; adverse events related to
the use of the product; improper estimation of the size of the
wound closure market; adverse results or unexpected delays in
clinical development processes; our ability to attract and retain
qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. and our ability to achieve the
operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
Quill(TM) is a trademark of Quill Medical, Inc, a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc. (C)2007 Angiotech
Pharmaceuticals, Inc. All Rights Reserved. About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company with over 1,500 dedicated
employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury.
To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Jodi Regts, Senior Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 221-7930, ; Analysts and Investors:
Deirdre Neary, Manager, Investor Relations, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Jodi Regts, Senior Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, ; Analysts and Investors: Deirdre Neary,
Manager, Investor Relations, Angiotech Pharmaceuticals, Inc., (604)
222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024